Highlight
The UK NCRI phase II PORT trial evaluated pembrolizumab immunotherapy followed by localized radiotherapy in relapsed/refractory cutaneous T-cell lymphoma (CTCL), including mycosis fungoides (MF) and Sézary syndrome (SS). This combination approach produced a meaningful overall response rate (ORR) and a subset of patients achieved durable remission beyond one year. The study advances understanding of combining immune checkpoint inhibitors with radiotherapy to boost systemic anti-tumor responses, particularly targeting the abscopal effect.
